SPC4955: Phase I started

Santaris began a double-blind, placebo-controlled, dose-escalation, German Phase I trial to evaluate single doses of 0.25, 0.5, 1, 1.5 and 2 mg/kg subcutaneous SPC4955 in 30 healthy volunteers. ...